Business Wire

CA-GLOBALLOGIC

30.11.2021 13:30:05 CET | Business Wire | Press release

Share
GlobalLogic Announces Partnership with Cybereason to Develop Advanced, Intelligent Cyber Protection Solutions

GlobalLogic Inc. , a Hitachi Group Company and leader in Digital Engineering, today announced that it has been selected by Cybereason, the leader in operation-centric attack protection, to help develop its next-generation cyber security platform and services. Deployed by large enterprises, governments, and major cloud providers worldwide, Cybereason’s future-ready attack protection spans across endpoints, the enterprise, the cloud, and everywhere the defenders battle cyber criminals. The collaboration will draw on GlobalLogic’s broad and deep expertise in security and data management software across devices through to the cloud, including the integration of advanced artificial intelligence (AI).

The program is one of the largest won by GlobalLogic in this field to date. It requires quickly scaling to hundreds of specialized engineers supporting Cybereason’s development roadmap over the next year. This program scope highlights the market’s need for stronger, better cybersecurity as cloud use, network expansions and other technology usage continued their upward trend and surged during the pandemic.

“Cyber threats have become considerably more frequent and sophisticated in recent years. We’ve become dangerously more vulnerable in areas traditional security solutions could not adequately protect—the network and the cloud,” said Rajaram Radhakrishnan, CRO, GlobalLogic. “Having operated in the cybersecurity space for more than a decade, GlobalLogic has become adept at successfully responding to complex requirements. Cybereason is a premier example of a crucial innovator building disruptive defense solutions, redefining what government-grade protection can be. We are honored to now be a part of their team.”

Cybereason delivers the most comprehensive protection available on the market today, analyzing more than 23 trillion security-related events per week—five times the volume of any other market solution. Using its patented Malicious Operations (MalOps™) engine, Cybereason reveals the full attack story across every device, user identity, application, and cloud deployment. One of Cybereason’s key solutions delivering this capability is the company’s Extended Detection and Response (XDR) solution —a unified detection and response tool that thwarts malicious operations across the entire IT stack. XDR is one of the several advanced technologies that GlobalLogic’s team will help Cybereason develop and enhance through the partnership.

“Cybereason’ operation-centric security approach is helping defenders combat sophisticated and persistent threats to their organizations. While other companies have security analysts chasing alerts without offering valuable insight, Cybereason helps organizations around the world leverage our award-winning technology each day to outthink and outpace attackers,” said Sam Curry, Chief Security Officer, Cybereason. “GlobalLogic’s track record along with its responsiveness and collaborative approach to R&D stood out as major factors in finalizing our partnership. Together, we will deliver next-gen cyber defense solutions that will help technology users better control their sensitive data and operations—no matter where they reside.”

About GlobalLogic

GlobalLogic (www.globallogic.com ) is a leader in digital engineering. We help brands across the globe design and build innovative products, platforms, and digital experiences for the modern world. By integrating experience design, complex engineering, and data expertise – we help our clients imagine what’s possible and accelerate their transition into tomorrow’s digital businesses. Headquartered in Silicon Valley, GlobalLogic operates design studios and engineering centers around the world, extending our deep expertise to customers in the automotive, communications, financial services, healthcare and life sciences, manufacturing, media and entertainment, semiconductor, and technology industries. GlobalLogic is a Hitachi Group Company operating under Hitachi, Ltd. (TSE: 6501), which contributes to a sustainable society with a higher quality of life by driving innovation through data and technology as the Social Innovation Business.

About Cybereason

Cybereason (www.cybereason.com ) is the champion for today’s cyber defenders, providing operation-centric attack protection that unifies security from the endpoint to the enterprise, to everywhere the battle moves. The Cybereason Defense Platform combines the industry’s top-rated AI-powered detection and response (EDR and XDR), next-gen antivirus (NGAV), Anti-Ransomware Protection and Proactive Threat Hunting to deliver context-rich analysis of every stage of a MalOp™ (malicious operation). Cybereason is a privately held, international company headquartered in Boston with customers in more than 40 countries.

GlobalLogic is a trademark of GlobalLogic. All other brands, products or service names are or may be trademarks or service marks of their respective owners.

Link:

ClickThru

Social Media:

https://www.facebook.com/GlobalLogic/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye